PLEASED TO SAY IS THE CEO OF NOVO NORDISK, MIKE DOUSTDAR. GREAT TO HAVE YOU WITH US. JUST TO SET THE SCENE WHEN IT COMES TO THE U.S. MARKET, YOU HAVE BEEN LOSING SHERRY TO ELI LILLY FOR A COUPLE YEARS NOW. WITH THIS APPROVAL, YOU HAVE AN IMPORTANT FIRST MOVER ADVANTAGE WHEN IT COMES TO ORAL GLP-1'S.GIVEN THAT YOU EXPECT TO SELL THE PILL VERSION OF WEGOVY IN JANUARY AND ELI LILLY IS NOT DUE UNTIL MARCH, HOW DO YOU PLAN TO MAKE THE MOST OF THIS HEAD START. MIKE: THANK YOU FOR HAVING ME. AS THEY SAY, CHRISTMAS ...

PLEASED TO SAY IS THE CEO OF NOVO NORDISK, MIKE DOUSTDAR. GREAT TO HAVE YOU WITH US. JUST TO SET THE SCENE WHEN IT COMES TO THE U.S. MARKET, YOU HAVE BEEN LOSING SHERRY TO ELI LILLY FOR A COUPLE YEARS NOW. WITH THIS APPROVAL, YOU HAVE AN IMPORTANT FIRST MOVER ADVANTAGE WHEN IT COMES TO ORAL GLP-1'S.GIVEN THAT YOU EXPECT TO SELL THE PILL VERSION OF WEGOVY IN JANUARY AND ELI LILLY IS NOT DUE UNTIL MARCH, HOW DO YOU PLAN TO MAKE THE MOST OF THIS HEAD START. MIKE: THANK YOU FOR HAVING ME. AS THEY SAY, CHRISTMAS ...

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) .Track LLY stock here.GLP-1 Demand Is Becoming StructuralThe obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and cardiovascular risk reduction.That long-t ...

1. 12月23日(周二)美股盘前，美股三大股指期货齐跌。截至发稿，道指期货跌0.05%，标普500指数期货 跌0.04%，纳指期货跌0.03%。 3. 截至发稿，WTI原油涨0.17%，报58.11美元/桶。布伦特原油涨0.21%，报62.20美元/桶。 市场消息 美国第三季度GDP今晚公布。美国经济在第三季度可能以较快的步伐增长，这主要得益于稳健的消费 者支出和商业投资。然而，受生活成本上升及近期政府停摆的影响，经济增长的势头似乎已有所减弱。 据调查估计，上季度GDP可能以3.3%的年化率增长。相比之下，第二季度的经济增速为3.8%。美国商 务部经济分析局(BEA)还将公布第三季度企业利润初值以及国内总收入(GDI)，后者是从收入角度衡量 经济增长的指标。无党派的国会预算办公室(CBO)估计，近期的政府停摆可能会使第四季度GDP下降1.0 至2.0个百分点。CBO预计，GDP的大部分下滑最终会得到回补，但预计仍有70亿至140亿美元的损失无 法挽回。尽管即将公布的第三季度GDP数据可能因时间久远而无法清晰反映当前状况，但交易员们也将 关注消费者数据，因为11月份的数据显示消费者信心大幅下滑。 美国银行CE ...

1.12月23日(周二)美股盘前，美股三大股指期货齐跌。截至发稿，道指期货跌0.05%，标普500指数期货跌0.04%，纳指 期货跌0.03%。 | 를 US 30 | 48,339.30 | 48.391.40 | 48,299.80 | -23.40 | -0.05% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,875.90 | 6,881.80 | 6,867.50 | -2.60 | -0.04% | | 트 US Tech 100 | 25,454.80 | 25,496.10 | 25,411.80 | -6.90 | -0.03% | 2.截至发稿，德国DAX指数涨0.07%，英国富时100指数涨0.02%，法国CAC40指数跌0.22%，欧洲斯托克50指数跌 0.13%。 | 3.截至发稿，WTI原油涨0.17%，报58.11美元/桶。布伦特原油涨0.21%，报62.20美元/桶。 | | --- | | | | 市场消息 收到多份收购提案，以星航运(ZIM.US)盘前涨近9%。以星航运盘前涨近9%，消息面上，美东时间12月22 ...

1. 12月23日(周二)美股盘前，美股三大股指期货齐跌。截至发稿，道指期货跌0.05%，标普500指数期货跌0.04%，纳 指期货跌0.03%。 | ■ US 30 | 48,339.30 | 48,391.40 | 48,299.80 | -23.40 | -0.05% | | --- | --- | --- | --- | --- | --- | | = US 500 | 6,875.90 | 6,881.80 | 6,867.50 | -2.60 | -0.04% | | 트 US Tech 100 | 25,454.80 | 25,496.10 | 25,411.80 | -6.90 | -0.03% | 2. 截至发稿，德国DAX指数涨0.07%，英国富时100指数涨0.02%，法国CAC40指数跌0.22%，欧洲斯托克50指数跌 0.13%。 | 3. 截至发稿，WTI原油涨0.17%，报58.11美元/桶。布伦特原油涨0.21%，报62.20美元/桶。 | | --- | 市场消息 美国第三季度GDP今晚公布。美国经济在第三季度可能以较快的步伐增长，这主要得益于稳健的消费者支出和商业投 资。然 ...

Group 1 - The company expects to launch the weight-loss pill in the U.S. in early January [1]

智通财经APP注意到，周二盘前，诺和诺德(NVO.US)股价上涨 7.5%，此前美国食品药品监督管理局 (FDA)批准了其减肥药片。这使该公司在快速演变的肥胖治疗市场中获得了竞争优势。 诺和诺德在 2021 年推出其注射药物 Wegovy 时曾面临巨大的供应链挑战，但公司表示这次已准备得更 加充分。首席执行官麦克·杜斯塔在 11 月曾表示，公司这次拥有"绰绰有余的药片"，并将"全力以赴"投 入产品上市。 Bellevue 资产管理公司的投资组合经理保罗·梅杰表示，口服减肥药可能会扩大市场，而不是蚕食注射 剂的市场份额，并补充说"10% 或更多的成年人对自我注射感到犹豫"。然而，他也质疑这些药片的变革 潜力，因为药片的疗效不如注射剂。 Sydbank 分析师索伦·朗托夫·汉森预测 Wegovy 药片的需求将十分强劲，估计全球年销售峰值约为 240 亿丹麦克朗(约合 37.9 亿美元)。他强调了此次发布对于抵消 2026 年预期逆风的重要性，其中包括 GLP- 1 药物定价可能下降的风险。 今年以来股价已下跌超过 50% 的诺和诺德，周二成为欧洲股市涨幅最大的个股。礼来盘前则下跌了 1%。 BMO 资本分析师埃文 ...

Core Insights - Novo Nordisk has received U.S. regulatory approval for its weight-loss pill, which may help the company recover from significant market capital loss and competition from Eli Lilly [1][2] - The approval comes after a challenging year for Novo, characterized by declining share prices, profit warnings, and slowing sales of its flagship product, Wegovy [2] Company Performance - Novo Nordisk's market capitalization has decreased from $650 billion in June last year to over $240 billion currently, indicating a loss of more than half its value [6] - The company's share price has significantly declined compared to its rivals over the past year [3] Competitive Landscape - Eli Lilly's Zepbound has surpassed Wegovy in U.S. prescriptions this year, marking a shift in the competitive dynamics of the obesity treatment market [2] - Novo was the first to market with Wegovy, approved in 2021, but has faced intensified competition since the launch of Zepbound in late 2023 [2] Financial Metrics - Novo's price-earnings ratio has returned to levels more in line with its peers, having previously commanded a significant premium [4] - The company has incurred rising costs due to investments in expanding manufacturing and sales capacity [5]

The CNBC app, global market news in one place. Customizable sections and personalized alerts. Stocks tracking, interactive charts and market insights, all in your hands.Stay connected, stay informed, download the CNBC app today. Welcome to Sportbox Europe. I'm Sylvia Maro with Karen Show.And here are your headlines this Tuesday morning. Europe stock 600 hits a record intraday high with equities edging higher as the investors eye today's GDP print out of the United States and no order shares bounce as the dr ...